SCHEMBL4697070

SCHEMBL4697070

CCOC(=O)c1nc2c(cnn2C)c(=O)[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.56
ALDH1A1 P00352 9/20 0.46
KDM4E B2RXH2 5/20 0.46
HPGD P15428 4/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 2/20 0.46
GAA P10253 2/20 0.46
POLB P06746 1/20 0.46
CYP2C19 P33261 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
NPC1 O15118 1/20 0.43
HIF1A Q16665 1/20 0.43
CYP3A4 P08684 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8198106 0.86 PTGS2 (0.44) PTGS2ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL20240233 0.85 PTGS2 (0.47) PTGS2ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL8196859 0.81 PTGS2 (0.84) PTGS2ALDH1A1CYP1A2CYP2C9MEN1
SCHEMBL8198110 0.80 ALDH1A1 (0.47) PTGS2ALDH1A1HPGDMEN1KMT2A
SCHEMBL4937298 0.80 ALDH1A1 (0.47) PTGS2ALDH1A1KDM4EHPGDCYP1A2
SCHEMBL20240237 0.79 ALDH1A1 (0.46) PTGS2ALDH1A1MEN1KMT2A
SCHEMBL8280814 0.79 PTGS2 (0.47) PTGS2ALDH1A1KDM4EHPGDCYP1A2
SCHEMBL25343807 0.76 PTGS2 (0.55) PTGS2ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL4926235 0.75 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDCYP1A2CYP2C9
SCHEMBL21818776 0.74 ALDH1A1 (0.46) ALDH1A1KDM4ECYP1A2GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383903-A1 Modulators of STING (Stimulator of Interferon Genes) PFIZER INC. (US) 2024-11-21 US disclosed
US-11964978-B2 Modulators of STING (stimulator of interferon genes) PFIZER INC. (US) 2024-04-23 US disclosed
EP-4308563-A1 MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) Pfizer Inc. (US) 2024-01-24 EP disclosed
CN-117321055-A Modulators of STING (interferon gene stimulators) 辉瑞公司 2023-12-29 CN disclosed
US-20220306641-A1 Modulators of STING (Stimulator of Interferon Genes) PFIZER INC. (US) 2022-09-29 US disclosed
WO-2022195462-A1 MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) PFIZER INC. (US) 2022-09-22 WO disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 PTGS2 1579/4885ALDH1A1 1978/4885KDM4E 1400/4885
US-11964978-B2 Modulators of STING (stimulator of interferon genes) STING1, IRF3, CGAS PTGS2 344/4885ALDH1A1 4771/4885KDM4E 3884/4885
US-20220306641-A1 Modulators of STING (Stimulator of Interferon Genes) STING1, IRF3, CGAS PTGS2 344/4885ALDH1A1 4771/4885KDM4E 3884/4885
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 PTGS2 681/4885ALDH1A1 1871/4885KDM4E 1572/4885
US-20240383903-A1 Modulators of STING (Stimulator of Interferon Genes) STING1, IRF3, CGAS PTGS2 344/4885ALDH1A1 4771/4885KDM4E 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.